论文部分内容阅读
众生药业(002317):公司2015年上半年收入7.5亿,同比增长19.87%,归母净利润1.49亿,同比增长27.45%,扣非增长26.45%,业绩符合预期,同时公告每10股派现金1元并转增10股。公司1-9月业绩预增20%~40%,保持较快增长。考虑到先强药业已并表,上调公司20152017年EPS至0.90(上涨0.12)元/股,维持目标价35元,对应2015年PE39X,维持增持评级。
Besen Pharmaceutical (002317): The Company recorded a revenue of 750 million in the first half of 2015, an increase of 19.87% over the same period of last year and a net profit of 149 million under its parent company, an increase of 27.45% over the same period of the previous year with a non-increase of 26.45% on non-growth basis. Its performance was in line with expectation, 1 yuan and increase by 10 shares. January-September performance of the company pre-20% to 40%, maintaining rapid growth. Considering that Xianqiang Pharmaceutical has been consolidated, the company raised EPS to 0.90 (up 0.12) Yuan / share in 20152017 and maintained the target price of 35 Yuan, corresponding to PE39X in 2015, maintaining the overweight rating.